Research indicates that in the management of patients with severe ANCA-associated vasculitis, azathioprine exerts an immunosuppressive effect during induction of remission, thereby lowering S100A8 and subsequently reducing the risk of recurrence for patients (68). This evidence concerns the gene S100A8 and anti-neutrophil cytoplasmic antibody-associated vasculitis.